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Insulin preparations: which one to choose? 
 
Eric Zini 
 
General aspects 
Diabetes mellitus (DM) in dogs and cats is suspected in the presence of clinical signs such as 
polyuria, polydipsia, polyphagia, and weight loss. Other clinical signs caused by DM are visual 
impairment secondary to diabetic cataract (dogs), plantigrade stance and generalized weakness 
due to diabetic polyneuropathy (cats), systemic hypertension (dogs), vomiting and lethargy 
induced by diabetic ketoacidosis, and pollakiuria and stranguria for cystitis. Blood alterations, such 
as hyperglycemia and increased serum concentration of fructosamine, and glycosuria are used to 
diagnose DM. It is important to remember that hyperglycemia and glycosuria may be induced by 
stress in cats; in these cases, fructosamine concentrations will be normal. Other laboratory 
abnormalities in diabetic dogs and cats are hypertriglyceridemia, hypercholesterolemia, and 
increased ALT and ALP (less likely in cats). The initial assessment of diabetic dogs and cats 
should be as complete as possible in order to identify any complications and concomitant or 
predisposing diseases that need to be treated along with DM. Concurrent diseases may cause 
resistance to insulin treatment or worsen the prognosis. 
 
Aims of treatment 
Treatment goals are resolution of clinical signs, control of body weight, and prevention of diabetic 
complications and episodes of hypoglycemia. In addition, in all diabetic cats and bitches with DM 
associated with diestrus and pregnancy, treatment should be aimed at achieving remission of 
disease. Remission of DM occurs in about 50% of diabetic cats and is defined as the 
disappearance of clinical signs for at least 4 weeks along with normalization of blood glucose 
despite discontinuation of insulin therapy. Remission occurs in the first 3–6 months after first 
diagnosis and is more likely if cats are elderly, have no polyneuropathy, have recently been treated 
with corticosteroids, and if strict glycemic control is initially provided (Zini et al. 2010). Even cats 
with ketoacidosis can achieve remission. In dogs, remission is rare with the exception of bitches in 
diestrus or pregnancy; remission in these cases is more likely if spaying is performed within 4 
weeks from onset of clinical signs or if hyperglycemia at diagnosis is not very high. The 
cornerstones of treatment in diabetic dogs and cats are administration of insulin and a dedicated 
diet (Rucinsky et al. 2010; Sparkes et al. 2015). The choice of insulin is often a dilemma for 
clinicians. 
 
Insulin preparations 
Short-acting insulins are preferred in animals with diabetic ketoacidosis or hyperosmolar 
syndrome, while insulins with an intermediate or long duration are administered in uncomplicated 
cases. The most widely used insulins and recommended for uncomplicated DM include: 
• Porcine insulin zinc suspension. Duration of effect 8–14 hours in dogs, 6–12 in cats. First 
choice in dogs, with an initial dosage of 0.25 UI/kg, twice daily. Not first choice in cats, 
because it can have a short duration. 
• Human recombinant protamine zinc insulin. Duration of effect 10–16 hours in dogs, 10–14 
in cats. First choice in cats with a starting dosage of 0.25 UI/kg, twice daily, without 
exceeding the dosage of 2 UI/cat for each administration. Not available in some countries. 
• Insulin glargine (recombinant human insulin analogue). Duration of effect 8–16 hours in 
cats (Gilor et al. 2010). First choice in this species (like the above) with an initial dosage of 
0.5 UI/cat for weight <2 kg, 1 UI/cat if £4 kg, and 1.5 UI/cat if > 4 kg. Do not exceed 1 UI/cat 
if the initial glucose concentration is <350 mg/dL. In dogs it is less beneficial than other 
insulins. It is not currently registered for dogs or cats. 
• Insulin detemir (recombinant human insulin analogue). Not first choice in both species. In 
cats with a starting dosage of 0.35 UI/kg, twice daily. In dogs with a starting dosage of 0.1 
UI/kg, twice daily; the small amounts make it difficult to administer or prone to errors 
(Fracassi et al. 2015). It is not currently registered for dogs or cats. 
Care must be taken with the use of insulins for human use because they have concentrations of 
100 UI/mL, while those registered for dogs and cats have concentrations of 40 UI/mL; it is 
therefore advisable to use the correct syringes for each type of insulin or make the correct 
conversion. Furthermore, it is suggested to administer insulin under the skin of the lateral chest 
and switch sides at each administration; this decreases the chances of local inflammation that in 
turn reduces insulin absorption. 
 
Oral antidiabetic drugs 
Oral hypoglycemic drugs are not commonly used in diabetic dogs and cats. In cats, glipizide 
(sulfonylurea) stimulates insulin secretion by β-cells. Glipizide is ineffective in diabetic dogs 
because they have almost a complete absence of β-cells. In cats, glipizide is used orally at an 
initial dosage of 2.5 mg/cat, twice daily; the dosage may be increased up to 5 mg/cat, twice daily, 
but vomiting and hepatocellular damage may occur. Glipizide is effective in approximately 30% of 
cats and promotes the deposition of amyloid. It may be used in cats that do not tolerate injections 
or when owners have poor compliance (Feldman et al. 1997). Acarbose, an inhibitor of the 
intestinal α-glucosidase, has been used in diabetic dogs and cats under insulin treatment with 
beneficial effects on mean glucose and fructosamine concentrations, although in the former 
species soft-watery were documented. 
 
Future perspectives, insulin and pumps 
The use of telemetrically-controlled pumps to deliver insulin glargine in the subcutaneous tissue of 
healthy cats has been recently reported (Zini et al. 2017). The pump during 4 weeks did not cause 
discomfort but life-threatening hypoglycaemia occurred soon after implantation in one cat. Stability 
of insulin glargine appeared to be acceptable based on in vitro experiments (Figure 1). Recently, a 
new pump has been developed and tested in a diabetic cat with poor metabolic control and owner 
compliance. Following 1-month of treatment the cat achieved remission of diabetes. A short-acting 
recombinant human insulin analogue able to endure for 45 days at 36 Celsius degrees was used 
(unpublished observation). Insulin was still effective in the cat after 30 days. 
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Figure 1. 
 
MALDI-TOF mass spectrometry in linear mode at the start of the trial (A) and after 8 weeks of 
agitation at 37°C (B) to determine the stability of insulin glargine. The peak with a molecular weight 
of approximately 6063 Daltons corresponds to the molecular weight of insulin glargine (red arrow). 
A second peak of approximately 12120 Daltons is identified at both time points, likely 
corresponding to aggregates of insulin glargine (dashed red arrow). Other peaks are indentified, 
likely corresponding to degradation products of insulin glargine. 
